Ghrelin Exerts Analgesic Effects through Modulation of IL-10 and TGF-β Levels in a Rat Model of Inflammatory Pain

Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-β are anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to pe...

Full description

Saved in:
Bibliographic Details
Published in:Iranian biomedical journal Vol. 21; no. 2; pp. 114 - 119
Main Authors: Azizzadeh, Faranak, Mahmoodi, Javad, Sadigh-Eteghad, Saeed, Farajdokht, Fereshteh, Mohaddes, Gisou
Format: Journal Article
Language:English
Published: Iran Pasteur Institute 01-03-2017
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-β are anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to peripheral and central inflammatory pain. In this study, the effects of i.p. injection of ghrelin on the early and the late phases of pain, as well as serum levels of IL-10 and TGF-β, as anti-inflammatory cytokines, were investigated in formalin-induced pain in male rats. Adult male Wistar rats (n=48) were randomly divided into six groups: control, formalin+saline, ghrelin (40, 80, and 160 μg/kg), and morphine. Ghrelin was administered i.p. 30 min before inducing pain by formalin. Pain induced by intraplantar (i.pl.) injection of 50 µl formalin 5%, and pain behavior was studied for 60 min. Serum IL-10 and TGF-β levels were assessed by ELISA method. The findings of the present study showed that ghrelin with high doses (80 and 160 μg/kg) significantly reduced pain intensity in both the early and the late phases of pain. The serum levels of cytokines, IL-10, and TGF-β1 showed a significant elevation with ghrelin at the dose of 160 μg/kg. Ghrelin is effective in reducing the intensity of both the early and the late phases of inflammatory pain. It seems that ghrelin exerts its analgesic effects in part by increasing the serum levels of anti-inflammatory cytokines.
AbstractList Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-β are anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to peripheral and central inflammatory pain. In this study, the effects of i.p. injection of ghrelin on the early and the late phases of pain, as well as serum levels of IL-10 and TGF-β, as anti-inflammatory cytokines, were investigated in formalin-induced pain in male rats. Adult male Wistar rats (n=48) were randomly divided into six groups: control, formalin+saline, ghrelin (40, 80, and 160 μg/kg), and morphine. Ghrelin was administered i.p. 30 min before inducing pain by formalin. Pain induced by intraplantar (i.pl.) injection of 50 µl formalin 5%, and pain behavior was studied for 60 min. Serum IL-10 and TGF-β levels were assessed by ELISA method. The findings of the present study showed that ghrelin with high doses (80 and 160 μg/kg) significantly reduced pain intensity in both the early and the late phases of pain. The serum levels of cytokines, IL-10, and TGF-β1 showed a significant elevation with ghrelin at the dose of 160 μg/kg. Ghrelin is effective in reducing the intensity of both the early and the late phases of inflammatory pain. It seems that ghrelin exerts its analgesic effects in part by increasing the serum levels of anti-inflammatory cytokines.
Background: Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-s are antiinflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to peripheral and central inflammatory pain. In this study, the effects of i.p. injection of ghrelin on the early and the late phases of pain, as well as serum levels of IL-10 and TGF-s, as anti-inflammatory cytokines, were investigated in formalin-induced pain in male rats. Methods: Adult male Wistar rats (n=48) were randomly divided into six groups: control, formalin+saline, ghrelin (40, 80, and 160 pg/kg), and morphine. Ghrelin was administered i.p. 30 min before inducing pain by formalin. Pain induced by intraplantar (i.pl.) injection of 50 pl formalin 5%, and pain behavior was studied for 60 min. Serum IL-10 and TGF-s levels were assessed by ELISA method. Results: The findings of the present study showed that ghrelin with high doses (80 and 160 pg/kg) significantly reduced pain intensity in both the early and the late phases of pain. The serum levels of cytokines, IL-10, and TGF-s1 showed a significant elevation with ghrelin at the dose of 160 pg/kg. Conclusion: Ghrelin is effective in reducing the intensity of both the early and the late phases of inflammatory pain. It seems that ghrelin exerts its analgesic effects in part by increasing the serum levels of anti-inflammatory cytokines.
BACKGROUNDGhrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-β are anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to peripheral and central inflammatory pain. In this study, the effects of i.p. injection of ghrelin on the early and the late phases of pain, as well as serum levels of IL-10 and TGF-β, as anti-inflammatory cytokines, were investigated in formalin-induced pain in male rats.METHODSAdult male Wistar rats (n=48) were randomly divided into six groups: control, formalin+saline, ghrelin (40, 80, and 160 μg/kg), and morphine. Ghrelin was administered i.p. 30 min before inducing pain by formalin. Pain induced by intraplantar (i.pl.) injection of 50 µl formalin 5%, and pain behavior was studied for 60 min. Serum IL-10 and TGF-β levels were assessed by ELISA method.RESULTSThe findings of the present study showed that ghrelin with high doses (80 and 160 μg/kg) significantly reduced pain intensity in both the early and the late phases of pain. The serum levels of cytokines, IL-10, and TGF-β1 showed a significant elevation with ghrelin at the dose of 160 μg/kg.CONCLUSIONGhrelin is effective in reducing the intensity of both the early and the late phases of inflammatory pain. It seems that ghrelin exerts its analgesic effects in part by increasing the serum levels of anti-inflammatory cytokines.
Author Sadigh-Eteghad, Saeed
Azizzadeh, Faranak
Farajdokht, Fereshteh
Mahmoodi, Javad
Mohaddes, Gisou
AuthorAffiliation 1 Drug Applied Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
2 Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
AuthorAffiliation_xml – name: 1 Drug Applied Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
– name: 2 Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
Author_xml – sequence: 1
  givenname: Faranak
  surname: Azizzadeh
  fullname: Azizzadeh, Faranak
  organization: Drug Applied Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
– sequence: 2
  givenname: Javad
  surname: Mahmoodi
  fullname: Mahmoodi, Javad
  organization: Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
– sequence: 3
  givenname: Saeed
  surname: Sadigh-Eteghad
  fullname: Sadigh-Eteghad, Saeed
  organization: Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
– sequence: 4
  givenname: Fereshteh
  surname: Farajdokht
  fullname: Farajdokht, Fereshteh
  organization: Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
– sequence: 5
  givenname: Gisou
  surname: Mohaddes
  fullname: Mohaddes, Gisou
  organization: Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27703278$$D View this record in MEDLINE/PubMed
BookMark eNqNkc9O3DAQh60KVBboI7TysZek_hs7l0oILVukRUVoD9wsx5nsBjk2tRNUXqsP0mdqgC2it548sn_zaTzfMToIMQBCHykpqdZV_cU6295PTdk3dyWjJSspFe_QghGiC8347QFaUMLmWrLbI3Sc8x0hXFKl3qMjphThTOkFSqtdAt8HvPwJacz4LFi_hdw7vOw6cPPNuEtx2u7wVWwnb8c-Bhw7fLkuKME2tHizuih-_8JreACf8Uyy-MaOT3Hwz8nQeTsMdozpEV_bPpyiw876DB_25wnaXCw359-K9ffV5fnZunBc1qIAUFqxlmsJlWCqlsAU4wJ0zVvHleSdIlXr2tY2tGmok4JXTEhRd1IL0fAT9PUFOy9pgNZBGJP15j71g02PJtre_PsS-p3ZxgcjmRKKkhnweQ9I8ccEeTRDnx14bwPEKRuqldKMSS7_IzqHKlKJJ6p8iboUc07QvU5EiXk2a_ZmzWzWMGqYmc3OfZ_efue1669K_gdrH6RI
CitedBy_id crossref_primary_10_1016_j_brainres_2020_146851
crossref_primary_10_1093_pm_pny280
crossref_primary_10_1002_tox_22840
crossref_primary_10_1002_biof_1490
crossref_primary_10_1007_s13105_022_00943_z
crossref_primary_10_3389_fnins_2023_1230428
crossref_primary_10_1038_s41598_019_51140_w
crossref_primary_10_3390_ijms18020273
crossref_primary_10_1007_s00586_022_07429_y
crossref_primary_10_1089_ham_2016_0132
crossref_primary_10_3390_ijms20102475
crossref_primary_10_1155_2020_1385138
crossref_primary_10_1007_s10753_020_01203_2
crossref_primary_10_2147_JEP_S249747
crossref_primary_10_1155_2017_4527980
crossref_primary_10_3389_fvets_2022_1016720
crossref_primary_10_2147_JPR_S260508
crossref_primary_10_1021_acs_jmedchem_1c02191
crossref_primary_10_1177_0333102417748563
crossref_primary_10_1016_j_clim_2022_108935
ContentType Journal Article
Copyright Copyright: © Iranian Biomedical Journal 2017
Copyright_xml – notice: Copyright: © Iranian Biomedical Journal 2017
CorporateAuthor Drug Applied Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
CorporateAuthor_xml – name: Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
– name: Drug Applied Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7QO
8FD
FR3
P64
5PM
DOI 10.18869/acadpub.ibj.21.2.114
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Biotechnology Research Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitleList MEDLINE
Engineering Research Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2008-823X
EndPage 119
ExternalDocumentID 10_18869_acadpub_ibj_21_2_114
27703278
Genre Journal Article
GroupedDBID ---
29J
2WC
3V.
53G
5GY
7X7
88E
8FI
8FJ
8R4
8R5
AAWTL
ABUWG
ACIWK
ACPRK
ADBBV
AFKRA
AFRAH
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BENPR
BPHCQ
BVXVI
CCPQU
CGR
CUY
CVF
CWDGH
DIK
E3Z
EBD
ECM
EIF
EMOBN
EOJEC
F5P
FRP
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
M1P
ML~
M~E
NPM
OBODZ
OK1
PQQKQ
PROAC
PSQYO
Q2X
RNS
RPM
SV3
TR2
UKHRP
W2D
XSB
AAYXX
CITATION
7X8
7QO
8FD
FR3
P64
5PM
ID FETCH-LOGICAL-c3594-ee7872d385e642795e27234e893dc3753f706dcddab1bb1c543624549f5844b3
IEDL.DBID RPM
ISSN 1028-852X
IngestDate Tue Sep 17 21:35:37 EDT 2024
Sat Aug 17 04:08:43 EDT 2024
Fri Jun 28 04:03:01 EDT 2024
Fri Aug 23 02:24:14 EDT 2024
Wed Oct 16 01:00:12 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords TGF-β
Pain
Ghrelin
IL-10
Formalin test
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c3594-ee7872d385e642795e27234e893dc3753f706dcddab1bb1c543624549f5844b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5274710/
PMID 27703278
PQID 1835360640
PQPubID 23479
PageCount 6
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5274710
proquest_miscellaneous_1877822535
proquest_miscellaneous_1835360640
crossref_primary_10_18869_acadpub_ibj_21_2_114
pubmed_primary_27703278
PublicationCentury 2000
PublicationDate 2017-03-00
2017-3-01
20170301
PublicationDateYYYYMMDD 2017-03-01
PublicationDate_xml – month: 03
  year: 2017
  text: 2017-03-00
PublicationDecade 2010
PublicationPlace Iran
PublicationPlace_xml – name: Iran
PublicationTitle Iranian biomedical journal
PublicationTitleAlternate Iran Biomed J
PublicationYear 2017
Publisher Pasteur Institute
Publisher_xml – name: Pasteur Institute
References 21474032 - Rev Bras Anestesiol. 2011 Mar-Apr;61(2):255-9, 260-5, 137-42
564014 - Pain. 1977 Dec;4(2):161-74
15491788 - Regul Pept. 2004 Nov 15;122(3):173-8
22125199 - Mol Neurobiol. 2012 Feb;45(1):76-86
22159099 - J Neurosci. 2011 Dec 7;31(49):17835-47
12359210 - Biochem Biophys Res Commun. 2002 Oct 4;297(4):700-13
27436480 - Neurosci Lett. 2016 Sep 6;630:30-7
1429677 - J Biol Chem. 1992 Nov 15;267(32):23301-8
17426506 - Int Anesthesiol Clin. 2007 Spring;45(2):27-37
9379845 - Brain Res Mol Brain Res. 1997 Aug;48(1):23-9
15117840 - Circulation. 2004 May 11;109(18):2221-6
15183037 - Front Neuroendocrinol. 2004 Apr;25(1):27-68
15135924 - Neurosci Lett. 2004 May 6;361(1-3):184-7
15107578 - J Pharmacol Sci. 2004 Apr;94(4):384-92
16215299 - Neurosignals. 2005;14(4):166-74
17362915 - Eur J Pharmacol. 2007 May 7;562(1-2):39-46
23500519 - Peptides. 2013 May;43:76-82
10988355 - Int J Immunopharmacol. 2000 Aug;22(8):603-14
15155307 - Anesth Analg. 2004 Jun;98(6):1566-73, table of contents
19327151 - Mol Pain. 2009 Mar 27;5:16
21565248 - Mol Cell Endocrinol. 2011 Jun 20;340(1):44-58
15006904 - Br J Pharmacol. 2004 Apr;141(7):1175-84
1472964 - Br J Pharmacol. 1992 Nov;107(3):660-4
11807165 - Annu Rev Pharmacol Toxicol. 2002;42:81-98
24113541 - Peptides. 2013 Dec;50:42-9
12651667 - Anesth Analg. 2003 Apr;96(4):1096-103, table of contents
19837031 - Cell. 2009 Oct 16;139(2):267-84
12483031 - Int Arch Allergy Immunol. 2002 Dec;129(4):263-76
22407485 - Amino Acids. 2012 Oct;43(4):1751-9
15232612 - J Clin Invest. 2004 Jul;114(1):57-66
23178578 - Exp Neurol. 2013 Feb;240:205-18
25647266 - Cytokine. 2015 Apr;72(2):121-9
18291254 - Surgery. 2008 Mar;143(3):334-42
24607724 - Peptides. 2014 May;55:103-9
16759671 - Neuropharmacology. 2006 Sep;51(3):497-505
References_xml
SSID ssj0035177
Score 2.2432444
Snippet Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of...
BACKGROUNDGhrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and...
Background: Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and...
SourceID pubmedcentral
proquest
crossref
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 114
SubjectTerms Analgesics - pharmacology
Animals
Disease Models, Animal
Full Length
Ghrelin - pharmacology
Inflammation - blood
Inflammation - complications
Interleukin-10 - blood
Male
Morphine - pharmacology
Nociception - drug effects
Pain - blood
Pain - complications
Rats, Wistar
Transforming Growth Factor beta - blood
Title Ghrelin Exerts Analgesic Effects through Modulation of IL-10 and TGF-β Levels in a Rat Model of Inflammatory Pain
URI https://www.ncbi.nlm.nih.gov/pubmed/27703278
https://search.proquest.com/docview/1835360640
https://search.proquest.com/docview/1877822535
https://pubmed.ncbi.nlm.nih.gov/PMC5274710
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9tAEB4RpEpcKkpLmz6iRep1nXgfsX1ENAHEQ6jNgZu1L7epyAbFiUT_Fj-kv6mzaxsBlXro2bP2eme884135huAz1xYh4ZkqB0LRQW6PJorltOqsKyQ6DSMDcXJJ9-yy-v8yyTQ5MiuFiYm7Rs9T_zNIvHzHzG38nZhhl2e2PDq4kjGUGo07EEPsWEXojfbL5dpbLcYHCfNJbtuy3byfFwMlVEWXzOZ658Jw-gwMOUGOuAMp8tCp7XHvukvwPk8b_KRI5ruwssWQZLDZqavYMv5PXjR9JT89RpWx6gdxI5kcudW65oE1pHvDnVBGqLimrStecjF0ra9u8iyIqfnuFcS5S2ZHU_p73tyHtKJaoJ3UuSrWgdxdxMlfYVmtIjH8-RKzf0bmE0ns6MT2jZWoIbLQlDn8DNllufSYfiRFdKxjHHhELtYwzGAqbLR2BprlU61To0U6OYERpIVwhWh-T5s-6V374BYHCBThYYw0iLXSslqJJxNtXLccOb6kHQrWt429BllCDuCNspWGyVqo2RpyUKFdB8OunUv0dDD6YXybrmpcQyXfBwOHv8lkwXEI7nsw9tGVw-P7ZTch-yJFh8EAtH20ytof5Fwu7W39_898gPssAAHYu7aR9herzbuE_RquxkgjD89G8RfAYNoyH8ACOL3Ew
link.rule.ids 230,315,729,782,786,866,887,27933,27934,53800,53802
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB7RIgQX3o_wXCSu69j7iO0jKklTkVQV5NCbtS-XoGZTxYkEf4sfwm9idm1XLUgcevas7dU3szOjnfkG4AMX1qEiGWpHQlGBLo8WihW0Li0rJToNY0Nz8vRrfnxafBoHmhzZ98LEon2jl4k_XyV--S3WVl6szLCvExuezA9kTKXS4R7cRntN0z5Jbw9gLrM4cDG4TlpIdto17hTFqBwqoyxuNFnq7wnD_DBw5QZC4Bx_mIVZa1e90z8h59-Vk1dc0eTBDTfxEO53sSf52D5-BLecfwx32mmUP5_A5hBxxaiTjH-4zbYhga_kzCGKpKU4bkg31IfM17ab-kXWNTma4SlLlLdkcTihv3-RWShEagi-SZEvahvE3XmU9DUq4Cpe7JMTtfRPYTEZLw6mtBvJQA2XpaDOoYEzywvpMHHJS-lYzrhwGPVYwzH1qfN0ZI21SmdaZ0YKdJACc9AaAx2h-TPY92vvXgCxuEBmClUo1aLQSsk6Fc5mWjluOHMDSHokqouWeKMKCUtAsepQrBDFimUVC73VA3jf41WhiYR7D-XdetfgGi75KFxZ_k8mD7GS5HIAz1uMLz_bK8cA8mvoXwoEiu7rTxD0SNXdgfzyxivfwd3pYj6rZkfHn1_BPRaCilgB9xr2t5udewN7jd29jQbwB-njCrY
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB7RIhAX3tDwXCSu68c-YvuI2qStSKsIcujNWu-uIajZRHEilb_FD-E3Mbu2oxYkDnD2rO3VN7Mzo535BuA9F8aiImlqhkJRgS6P5orltC4MKyQ6DW18c_LJ5-z8Ij8aeZqc3aivULSvq3nkLheRm38NtZWrhY77OrF4enYoQyqVxCtTx3twG202YX2i3h7CXKZh6KJ3nzSX7KJr3snzYRErrQxuNppX3yKGOaLny_WkwBn-NPPz1q57qD_Czt-rJ6-5o_GD_9jIQ7jfxaDkQyvyCG5Z9xjutFMpvz-B9THii9EnGV3Z9aYhnrfki0U0SUt13JBuuA85W5pu-hdZ1uR0gqctUc6Q2fGY_vxBJr4gqSH4JkU-qY0Xt5dB0tWoiItwwU-mau6ewmw8mh2e0G40A9VcFoJai4bODM-lxQQmK6RlGePCYvRjNMcUqM6SodHGqCqtqlRLgY5SYC5aY8AjKv4M9t3S2QMgBhfIVKEqJZXIK6VknQhr0kpZrjmzA4h6NMpVS8BR-sTFI1l2SJaIZMnSkvke6wG86zEr0VT8_YdydrltcA2XfOivLv8mk_mYSXI5gOctzrvP9goygOyGBuwEPFX3zScIfKDs7oB-8c8r38Ld6dG4nJyef3wJ95iPLUIh3CvY36y39jXsNWb7JtjAL0lVDTY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ghrelin+Exerts+Analgesic+Effects+through+Modulation+of+IL-10+and+TGF-+beta+Levels+in+a+Rat+Model+of+Inflammatory+Pain&rft.jtitle=Iranian+biomedical+journal&rft.au=Azizzadeh%2C+Faranak&rft.au=Mahmoodi%2C+Javad&rft.au=Sadigh-Eteghad%2C+Saeed&rft.au=Farajdokht%2C+Fereshteh&rft.date=2017-03-01&rft.issn=1028-852X&rft.volume=21&rft.issue=2&rft.spage=114&rft.epage=114&rft_id=info:doi/10.18869%2Facadpub.ibj.21.2.114&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1028-852X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1028-852X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1028-852X&client=summon